AXL in cancer: a modulator of drug resistance and therapeutic target

被引：34
|
作者：
Tang, Yaoxiang [1 ]
Zang, Hongjing [1 ]
Wen, Qiuyuan [1 ]
Fan, Songqing [1 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2023年 / 42卷 / 01期
基金：
中国国家自然科学基金;
关键词：
AXL; Cancer; Drug resistance; Target therapy; Molecular mechanisms; RECEPTOR TYROSINE KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; BREAST-CANCER; DNA-DAMAGE; GAS6/AXL AXIS; EGFR-TKI; INHIBITION; PROMOTES;
D O I：
10.1186/s13046-023-02726-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance. Recent studies revealed that reducing AXL expression can weaken cancer cells' drug resistance, indicating that AXL may be a promising target for anti-cancer drug treatment. This review aims to summarize the AXL's structure, the mechanisms regulating and activating it, and its expression pattern, especially in drug-resistant cancers. Additionally, we will discuss the diverse functions of AXL in mediating cancer drug resistance and the potential of AXL inhibitors in cancer treatment.
引用
收藏
页数：14
相关论文
共 50 条
  • [41] Drug Insight: VEGF as a therapeutic target for breast cancer
    Schneider, Bryan P.
    Sledge, George W., Jr.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (03): : 181 - 189
  • [42] Drug Insight: VEGF as a therapeutic target for breast cancer
    Bryan P Schneider
    George W Sledge
    Nature Clinical Practice Oncology, 2007, 4 : 181 - 189
  • [43] The receptor tyrosine kinase, Axl, as a therapeutic target in malignant melanoma
    Szentpetery, Z.
    Lovat, P. E.
    Bergamaschi, D.
    O'Toole, E. A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S240 - S240
  • [44] Mechanisms of resistance in prostate cancer: AMPK as a therapeutic target
    Sanchez, B. G.
    Bort, A.
    Mateos-Gomez, P. A.
    Rodriguez-Henche, N.
    Diaz-Laviada, I.
    FEBS OPEN BIO, 2019, 9 : 324 - 324
  • [45] AXL as a therapeutic target in STK11 mutant NSCLC
    Blo, Magnus
    Rayford, Austin
    Madeleine, Noelly
    Gartner, Fabian
    Bohan, Dana
    Ruggio, Natalie
    Li, Huiyu
    Girard, Luc
    Brekken, Rolf
    Minna, John
    Anerud, Marianne
    Maury, Wendy
    Gorcea-Carson, Claudia
    Gausdal, Gro
    Micklem, David R.
    McCracken, Nigel
    CANCER RESEARCH, 2023, 83 (07)
  • [46] AXL kinase as a novel target for cancer therapy
    Wu, Xiaoliang
    Liu, Xuewen
    Koul, Sanjay
    Lee, Chang Youl
    Zhang, Zhenfeng
    Halmos, Balazs
    ONCOTARGET, 2014, 5 (20) : 9546 - 9576
  • [47] AXL is strongly activated and a potential target for therapeutic intervention in mesothelioma
    Ou, Wen-bin
    Bueno, Raphael
    Sugarbaker, David
    Fletcher, Jonathan
    CANCER RESEARCH, 2009, 69
  • [48] AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew
    Auyez, Almira
    Sayan, A. Emre
    Kriajevska, Marina
    Tulchinsky, Eugene
    CANCERS, 2021, 13 (19)
  • [49] Axl inhibitors as novel cancer therapeutic agents
    Shen, Yingying
    Chen, Xiguang
    He, Jun
    Liao, Duanfang
    Zu, Xuyu
    LIFE SCIENCES, 2018, 198 : 99 - 111
  • [50] Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications
    Yang, Fei-Fei
    Xu, Xue-Li
    Hu, Ting
    Liu, Jian-Quan
    Zhou, Jin-Zhu
    Ma, Li-Ying
    Liu, Hong-Min
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (07) : 4275 - 4293
12345